Tissue specific mechanism of FXR in suppressing bile-acid synthesis

FXR抑制胆汁酸合成的组织特异性机制

• 批准号: 8106415
• 负责人: GRACE L GUO
• 金额: $ 26.49万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-10 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8106415
• 关键词: Animal Model; Atherosclerosis; Bile Acid Biosynthesis Pathway; Bile Acids; Bile fluid; Biliary; Blood; Cardiovascular Diseases; Cell physiology; Cells; Cholelithiasis; Cholestasis; Cholesterol; Cholesterol 7-alpha-Monooxygenase; Congenic Mice; Data; Development; Disease; Drug Delivery Systems; Enterocytes; Enzymes; FGFR4 gene; Fatty Liver; Feedback; Fibroblast Growth Factor; Functional disorder; Future; Gene Expression; Genes; Genetic; Goals; Growth; Hepatic; Hepatocyte; Homeostasis; Homologous Gene; In Vitro; Intestines; JUN gene; Knockout Mice; Ligands; Light; Lipids; Liver; Liver diseases; Liver neoplasms; Lymph; MAPK3 gene; MAPK8 gene; Mediating; Mesentery; Minor; Mixed Function Oxygenases; Molecular; Mus; Nuclear Receptors; Pathway interactions; Phosphotransferases; Prevention; Protein Kinase; Proteins; Receptor Activation; Receptor Gene; Recombinant Proteins; Regulation; Research; Role; Route; Signal Pathway; Signal Transduction; Signaling Molecule; Techniques; Testing; Tissues; Travel; Triglycerides; Work; base; congenic; design; extracellular; glucose metabolism; human disease; inhibitor/antagonist; innovation; lipid disorder; lipid metabolism; mouse model; prevent; public health relevance; receptor; response; small heterodimer partner protein

DESCRIPTION (provided by applicant): Bile acids are mainly produced in the liver with cholesterol 7a hydroxylase (cyp7a1) the rate-limiting enzyme. Bile acids are involved in liver, biliary, intestinal, and cardiovascular diseases. FXR is a bile-acid activated nuclear receptor and is essential in maintaining bile-acid homeostasis. FXR dysfunction contributes to the development of cholestasis, gallstones, fatty-liver disease, and liver tumor. Emerging evidence suggest that in mice FXR suppresses cyp7a1 gene expression via pathways initiated both in the liver and the intestine. However, to understand the roles of FXR in suppressing bile-acid synthesis, clear gaps exist in consolidating where the suppressive pathway initiates, to what extent SHP and FGF15 are involved, and what signaling molecules are in the liver to suppress cyp7a1 gene expression. The objective of this application is to establish the underlying molecular mechanism by which FXR regulates bile-acid synthesis in a tissue-specific manner. My hypothesis is that intestine-initiated FGF15- FGR4 pathway is the major and the liver-initiated SHP-LRH-1 cascade is a minor underlying mechanism for suppressing cyp7a1 with FXR activation, in addition, both Egr-1 and cJun are involved in FGFR4 pathway to suppress cyp7a1 gene expression. The hypothesis is based on our compelling preliminary data that collectively showed that FXR, but not SHP, intestinal FXR, but not hepatic FXR, is mainly responsible for the suppression of cyp7a1 gene expression. We plan to test the hypothesis and accomplish the objective by pursuing the following specific aims. (1) Establish the tissue-specific function of FXR in suppressing cyp7a1 gene expression. (2) Determine to what extent that SHP and FGF15 are involved in suppressing cyp7a1 and regulating bile-acid homeostasis. (3) Elucidate the signaling pathways for suppressing cyp7a1 gene expression following FGFR4 activation. The proposed research is innovative and represents a paradigm shift in understanding the regulation of bile-acid synthesis. We are the first to combine the usage of tissue-specific FXR KO mice with cellular and molecular techniques to identify the fundamental pathways in regulating bile-acid feedback inhibition. These studies will identify the tissue specific roles of FXR, which will provide a fundamental understanding for the study of bile-acid, cholesterol, and triglyceride homeostasis. Furthermore, completion of the proposed study will shed light on designing tissue-specific FXR modulators in the future to better prevent and treat human diseases associated with bile-acid disorders. Public Health Relevance: Bile acids are the main components in bile and are important for regulating cholesterol and triglyceride homeostasis. FXR is essential in regulating bile-acid homeostasis, and contributes to the development of cholestasis, gallstones, fatty-liver disease, liver tumors, and atherosclerosis. Completion of the proposed study will shed light on designing tissue-specific FXR modulators in the future to better prevent and treat human diseases associated with bile-acid disorders.

性状（由申请人提供）：胆汁酸主要在肝脏中由胆固醇7a羟化酶（cyp 7a 1）（限速酶）产生。胆汁酸与肝、胆、肠和心血管疾病有关。FXR是一种胆汁酸激活的核受体，在维持胆汁酸稳态中至关重要。FXR功能障碍有助于胆汁淤积、胆结石、脂肪肝疾病和肝肿瘤的发展。新出现的证据表明，在小鼠中，FXR通过在肝脏和肠道中启动的途径抑制cyp 7a 1基因表达。然而，为了理解FXR在抑制胆汁酸合成中的作用，在巩固抑制途径起始的位置、SHP和FGF 15参与的程度以及肝脏中抑制cyp 7a 1基因表达的信号分子方面存在明显的差距。本申请的目的是建立FXR以组织特异性方式调节胆汁酸合成的潜在分子机制。我的假设是，FXR激活抑制cyp 7a 1的主要机制是由苦参碱启动的FGF 15-FGR 4通路，而肝脏启动的SHP-LRH-1级联反应是次要的潜在机制，此外，Egr-1和cJun均参与FGFR 4通路抑制cyp 7a 1基因表达。这一假设是基于我们令人信服的初步数据，这些数据共同表明，FXR，而不是SHP，肠道FXR，而不是肝脏FXR，主要负责cyp 7a 1基因表达的抑制。我们计划通过追求以下具体目标来检验假设并实现目标。(1)建立FXR抑制cyp 7a 1基因表达的组织特异性功能。(2)确定SHP和FGF 15在多大程度上参与抑制cyp 7a 1和调节胆汁酸稳态。(3)阐明FGFR 4激活后抑制cyp 7a 1基因表达的信号通路。拟议的研究是创新的，代表了理解胆汁酸合成调控的范式转变。我们是第一个将组织特异性FXR KO小鼠的使用与细胞和分子技术结合联合收割机来确定调节胆汁酸反馈抑制的基本途径的人。这些研究将确定FXR的组织特异性作用，这将为胆汁酸，胆固醇和甘油三酯稳态的研究提供基本的理解。此外，拟议研究的完成将有助于未来设计组织特异性FXR调节剂，以更好地预防和治疗与胆汁酸紊乱相关的人类疾病。公共卫生相关性：胆汁酸是胆汁中的主要成分，对调节胆固醇和甘油三酯体内平衡很重要。FXR在调节胆汁酸稳态中是必不可少的，并且有助于胆汁淤积、胆结石、脂肪肝疾病、肝肿瘤和动脉粥样硬化的发展。这项研究的完成将有助于未来设计组织特异性FXR调节剂，以更好地预防和治疗与胆汁酸紊乱相关的人类疾病。